Indication

Leukocyte adhesion deficiency type 1 (LAD-1)

Leukocyte adhesion deficiency type 1 (LAD-1) is a rare, life-threatening autosomal recessive primary immunodeficiency disorder caused by pathogenic variants in the *ITGB2* gene, which encodes the beta-2 integrin subunit CD18. Read more about Leukocyte adhesion deficiency type 1 (LAD-1)

1 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Leukocyte adhesion deficiency type 1 (LAD-1) therapies.

Showing 1–1 of 1 drugs

Filter & compare in the drug finder →Opens the drug finder with Leukocyte adhesion deficiency type 1 (LAD-1) preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Leukocyte adhesion deficiency type 1 (LAD-1).

Leukocyte adhesion deficiency type 1 (LAD-1) is a rare, life-threatening autosomal recessive primary immunodeficiency disorder caused by pathogenic variants in the *ITGB2* gene, which encodes the beta-2 integrin subunit CD18.

This genetic defect disrupts leukocyte adhesion and prevents neutrophils from transmigrating across vascular endothelium into infected or inflamed tissues.

Characterized primarily in pediatric populations, hallmark clinical features include delayed separation of the umbilical cord, severe omphalitis, impaired wound healing, persistent peripheral blood leukocytosis, and recurrent, non-purulent bacterial and fungal infections affecting the skin and mucous membranes.

Personalize your experience

Follow Leukocyte adhesion deficiency type 1 (LAD-1) and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it